Quantcast

Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation

August 14, 2014

BERGISCH GLADBACH, Germany, August 14, 2014 /PRNewswire/ –

Addition of lentiviral gene delivery capabilities complements strategic partnering
portfolio.

Miltenyi Biotec announced today that it has acquired the lentiviral vector
manufacturing business and related assets from US company Lentigen Corporation, a global
leader in lentiviral technology for cell and gene therapy applications.

The acquisition further strengthens Miltenyi Biotec’s portfolio in cell and gene
therapy. Assets obtained in the transaction include a broad range of intellectual
property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen
team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US
subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

Miltenyi Biotec will leverage the combined capabilities by offering customized system
and application design in strategic partnerships with clinical investigators and companies
to develop and commercialize cell and gene therapies.

“It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors
for cell and gene therapies, both for clinical research and at commercial scale,” said
Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. “With the acquisition of the
Lentigen assets, we have strengthened our comprehensive portfolio that will enable our
current and future partners to proceed in cell therapies efficiently from preclinical
testing through human studies to automated manufacturing for widespread commercial
therapeutic use, all with a single strategic partner.”

Lentiviral technology provides the most efficient method for delivering genetic
material into cells to modulate their function, as demonstrated by recent clinical trials
in genetic diseases and oncology indications utilizing lentivirus-modified chimeric
antigen receptor (CAR) T cells.

Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have
been granted certain rights to deploy lentiviral technology in some therapeutic
indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing
supplier.

About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical
research and cellular therapy. The company’s integrated tools support research at every
level, from basic research to translational research to clinical application. Their
technologies cover techniques of sample preparation, cell isolation, flow sorting, flow
cytometry, cell culture, molecular analysis, and preclinical imaging. The company’s more
than 25 years of expertise spans research areas including immunology, stem cell biology,
neuroscience, and cancer, and clinical research areas like hematology, graft engineering,
and apheresis. Trusted around the world, the Miltenyi Biotec brand continues to set new
standards in the industry. Miltenyi Biotec has more than 1,400 employees in 25 countries.

        Media Contact:
        Claire England
        Tel: +44-(0)1480-471045
        claire.england@phoenixmarcom.co.uk

SOURCE Miltenyi Biotec


Source: PR Newswire



comments powered by Disqus